The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Exploratory analysis of the visceral disease (VD) patient subset in COU-AA-301, a phase III study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).
Oscar B. Goodman
Consultant or Advisory Role - Veridex
Honoraria - Veridex
Thomas W. Flaig
Consultant or Advisory Role - Sanofi
Honoraria - Amgen
Research Funding - Amgen; Cougar Biotechnology; Medivation; Sanofi ; Veridex
Other Remuneration - Cougar Biotechnology
Arturo Molina
Employment or Leadership Position - Janssen Pharmaceutical
Stock Ownership - Johnson & Johnson
Peter Mulders
Consultant or Advisory Role - Astellas Pharma; AstraZeneca; GlaxoSmithKline; Johnson & Johnson
Honoraria - Janssen Pharmaceutical ; Johnson & Johnson
Research Funding - Bayer
Henrik Suttmann
Consultant or Advisory Role - Astellas Pharma; Ferring; Ipsen; Janssen-Cilag; Janssen-Cilag; Medac; Sanofi
Honoraria - Janssen-Cilag
Research Funding - Astellas Pharma; Janssen-Cilag
Jinhui Li
Employment or Leadership Position - Janssen Pharmaceutical ; Janssen R&D
Stock Ownership - Johnson & Johnson; Johnson & Johnson
Thian San Kheoh
Employment or Leadership Position - Janssen Pharmaceutical
Stock Ownership - Johnson & Johnson
Johann Sebastian De Bono
Employment or Leadership Position - The Institute of Cancer Research ; The Institute of Cancer Research ; The Institute of Cancer Research ; The Institute of Cancer Research
Consultant or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson
Honoraria - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson
Howard I. Scher
Consultant or Advisory Role - Amgen; Amgen; Amgen; Aragon Pharmaceuticals; Aragon Pharmaceuticals; Aragon Pharmaceuticals; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Centocor Ortho Biotech; Centocor Ortho Biotech; Centocor Ortho Biotech; Cougar Biotechnology; Cougar Biotechnology; Cougar Biotechnology; Exelixis; Exelixis; Exelixis; Foundation Medicine; Foundation Medicine; Foundation Medicine; Janssen; Janssen Global; Janssen Global; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Medivation; Medivation; Medivation; Millennium; Millennium; Millennium; Novartis; Novartis; Novartis; Orion/Endo; Orion/Endo; Orion/Endo; Sanofi ; Sanofi ; Sanofi ; Veridex; Veridex; Veridex
Stock Ownership - Genta; Genta; Genta; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson
Honoraria - Amgen; Amgen; Amgen; Centocor Ortho Biotech; Centocor Ortho Biotech; Centocor Ortho Biotech; Millennium; Millennium; Millennium; Novartis; Novartis; Novartis; Orion/Endo; Orion/Endo; Orion/Endo; Sanofi ; Sanofi ; Sanofi
Research Funding - Aragon Pharmaceuticals; Aragon Pharmaceuticals; Aragon Pharmaceuticals; Centocor Ortho Biotech; Centocor Ortho Biotech; Centocor Ortho Biotech; Cougar Biotechnology; Cougar Biotechnology; Cougar Biotechnology; Exelixis; Exelixis; Exelixis; Medivation; Medivation; Medivation; Veridex; Veridex; Veridex
Other Remuneration - Amgen; Amgen; Amgen; AstraZeneca; AstraZeneca; AstraZeneca; Cougar Biotechnology; Cougar Biotechnology; Cougar Biotechnology; Exelixis; Exelixis; Exelixis; Medivation; Medivation; Medivation; Millennium; Millennium; Millennium; Novartis; Novartis; Novartis; Orion/Endo; Orion/Endo; Orion/Endo; Sanofi ; Sanofi ; Sanofi